The acquisition of Lunaphore Technologies will complement Bio-Techne's leading spatial biology franchise, as Lunaphore's technology enables the identification of biomarker signatures with clinical relevance. This will support the development of diagnostic tools and streamline clinical trials, ultimately improving patient outcomes. The acquisition is expected to close in Q3, and it is likely to have a positive short-term impact on Bio-Techne's stock price.